PHAXIAM Therapeutics S.A.
$3.10-5.20%($-0.17)
TickerSpark Score
53/100
87
Valuation
65
Profitability
15
Growth
68
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHXM research report →
52-Week Range6% of range
Low $2.50
Current $3.10
High $13.00
Companywww.erytech.com
PHAXIAM Therapeutics S. A. , a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
- CEO
- Eric Soyer
- IPO
- 2017
- Employees
- 49
- HQ
- Lyon, FR
Price Chart
-58.94% · this period
Valuation
- Market Cap
- $19.86M
- P/E
- -0.02
- P/S
- 0.76
- P/B
- 0.02
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1784.31%
- Net Margin
- -1771.34%
- ROE
- -95.68%
- ROIC
- -56.27%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-23,488,000 · -10247.14%
- EPS
- $-4.62 · -4520.00%
- Op Income
- $-25,417,000
- FCF YoY
- 22.81%
Performance & Tape
- 52W High
- $13.00
- 52W Low
- $2.50
- 50D MA
- $3.88
- 200D MA
- $5.17
- Beta
- 1.80
- Avg Volume
- 1.89K
Get TickerSpark's AI analysis on PHXM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PHXM Coverage
We haven't published any research on PHXM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHXM Report →Similar Companies
MEIP+10.43%
MEI Pharma, Inc.
$3.07
NYMXF+38.00%
Nymox Pharmaceutical Corporation
$0.10
MTVA+53.72%
MetaVia Inc.
$2.89
TRAW+1.89%
Traws Pharma, Inc.
$1.62
CSCI+0.00%
COSCIENS Biopharma Inc.
$2.72
PIRS-15.58%
Pieris Pharmaceuticals, Inc.
$13.60
DOMH+5.88%
Dominari Holdings Inc.
$3.24
ELEV-2.12%
Elevation Oncology, Inc.
$0.36